In 2017, the first therapeutic germline intervention using CRISPR-Cas9 was reported, where researchers corrected the genetic defects of zygotes resulting from the microinjection of sperm with the MYBPC3 mutation, which predisposes the offspring to develop hypertrophic cardiomyopathy [178]. Here, MYBPC3 is linked to hypertrophic cardiomyopathy.